December 2, 2020: The UN Breaks a 59-Year Policy Position on Cannabis
Published December 2, 2020 — By Ann Karim, Senior Cannabis Editor
- The UN Commission on Narcotic Drugs (CND) voted 27-25 on December 2, 2020 to remove cannabis from Schedule IV of the 1961 Single Convention
- Cannabis had been in Schedule IV — alongside heroin — since the 1961 Convention, treated as having no medical value
- Cannabis remains in Schedule I, meaning international drug controls still apply
- The US voted yes under the Trump administration — a significant diplomatic shift
- China, Russia, and most developing nations voted no; most Western democracies voted yes
- The WHO’s 2019 expert review recommended the change, citing evidence of medical utility and disproportionate scheduling
What Schedule IV Actually Was and Why It Mattered
To understand the significance of December 2020’s UN vote, it helps to understand what Schedule IV of the 1961 Single Convention actually meant. The 1961 Convention — signed by most nations and the foundational document of the global drug control regime — created four schedules of controlled substances. Schedule I included drugs subject to international control. Schedule IV was the most restrictive designation, reserved for substances considered to have “particularly dangerous properties” with “little or no medical use.” Cannabis had shared Schedule IV with heroin since 1961.
The Schedule IV designation had treaty-level implications. Countries that are parties to the 1961 Convention are obligated to apply particular restrictions to Schedule IV substances, including prohibiting or severely restricting their production, manufacture, and trade. For nations trying to build medical cannabis programs within their domestic legal frameworks, the Schedule IV listing created treaty compliance complications that some governments cited as obstacles to reform.
Removing cannabis from Schedule IV did not remove it from international controls entirely — cannabis remained in Schedule I, which still requires signatory nations to control its use. But the removal from Schedule IV removed the explicit treaty-level determination that cannabis has no medical value, clearing the path for national medical cannabis programs to operate with fewer treaty-compliance concerns. It was a symbolic and diplomatic change as much as a legally operational one.
“Today’s vote is a recognition of the growing body of scientific evidence that cannabis has legitimate medical applications. It does not end the debate — it reframes it.” — cannabis policy analyst, December 2, 2020
The 27-25 Vote: Who Voted Which Way and Why
The 27-25-1 vote reflected a geopolitical fault line in cannabis reform. The yes coalition was led by the United States (voting yes under the Trump administration in a notable policy position), supported by most EU member states, Canada, the UK, Australia, and New Zealand. The no coalition was anchored by China and Russia, with support from Pakistan, Nigeria, Egypt, Brazil, Algeria, and most nations in the Middle East, North Africa, and developing world. Japan abstained.
The US yes vote deserves particular attention. The Trump administration had shown no particular enthusiasm for cannabis reform domestically, but the State Department’s vote yes at the CND was consistent with US pharmaceutical industry interests: clearing Schedule IV obstacles to cannabis-based medicine research and products was commercially beneficial. The Biden administration, which took office in January 2021, continued this position. The US vote signaled that even the world’s most globally influential drug prohibition regime had accepted that cannabis Schedule IV treatment was scientifically unjustifiable.
Countries voting no reflected a coalition of governments that see cannabis reform as a threat to their domestic social order, a capitulation to Western cultural imperialism, or a practical challenge given their limited capacity to regulate a newly legal market. The narrow margin — two votes would have changed the outcome — demonstrated how contested international cannabis policy remains and how significant the diplomatic groundwork for the December 2020 vote had been. For context on where cannabis laws stand globally, the CND vote was a diplomatic data point but not a legal transformation.
What the WHO’s 2019 Scientific Review Found
The December 2020 vote was the culmination of a process that began with a comprehensive WHO Expert Committee on Drug Dependence (ECDD) review in 2019. The WHO’s review was the most thorough scientific reassessment of cannabis’ international scheduling in decades. The committee reviewed hundreds of studies on cannabis’ medical utility, abuse potential, safety profile, and the evidence base for its current scheduling under the 1961 Convention.
The committee’s findings were clear: cannabis has documented medical utility, particularly for pain, nausea, and specific forms of epilepsy. The CBD component of cannabis is not psychoactive, has no abuse potential, and has demonstrated medical value — leading to a separate recommendation to remove CBD from international controls entirely, which the CND accepted. The placement of cannabis in Schedule IV alongside heroin was not scientifically justified given the evidence base for medical applications and the differences in harm profile between the two substances.
The WHO’s recommendations covered several dimensions of cannabis scheduling. Beyond Recommendation 5.1 (the Schedule IV removal), the committee recommended various changes to how cannabis preparations were treated under the 1971 Psychotropic Substances Convention. Some of these additional recommendations were rejected by the CND, reflecting the ongoing political nature of scheduling decisions even when scientific recommendations are clear. For consumers interested in the medical science of cannabinoids including terpenes and non-psychoactive compounds, the WHO review represents the most authoritative international scientific assessment of cannabis’ pharmaceutical properties.
What the Vote Changed — and What It Left Unchanged
The December 2020 vote was historically significant but operationally modest in its immediate effects. Cannabis did not become legal internationally. The 1961 Convention’s Schedule I requirements still applied. Nations that had legalized cannabis recreationally — Canada, Uruguay, and by this point numerous US states — remained technically in breach of their international treaty obligations. The reclassification did not resolve that tension.
What changed was the diplomatic and scientific standing of cannabis reform globally. Countries could now build national medical cannabis programs without the Schedule IV designation being cited as a treaty barrier. International pharmaceutical companies could pursue cannabis-derived drug development with greater clarity about their products’ standing under international law. Research institutions could seek funding and approval for cannabis research without the Schedule IV stigma complicating ethical and regulatory review processes.
For countries considering legalization, the December 2020 vote provided diplomatic cover. Germany, which began its legalization process in 2021 and implemented adult-use reform in 2024, cited the evolving international framework — including the CND reclassification — as part of the context for its domestic reform. The vote did not create a legal license to legalize, but it removed one of the treaty-based arguments that opponents of legalization had routinely deployed. In the landscape of global cannabis law, December 2020 marked the moment when the international institutional framework began, however slowly, catching up to the reality of national-level reform.